NF-κB, IL-6 and myeloma cell growth: Making the connection

Cancer Biology and Therapy

Volumn 3, Issue 10, 2004, Pages 1018-1020

  Chiang, Mark Y ^a   Stadtmauer, Edward A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AP 1; C EBP; CREB; Gene expression; IL 6; Multiple myeloma; NF B

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ARSENIC TRIOXIDE; BORTEZOMIB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEXAMETHASONE; DNA; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; LUCIFERASE; MUTANT PROTEIN; PROTEIN C JUN; PROTEIN INHIBITOR; PROTEIN P300; PROTEIN P50; SYNAPTOTAGMIN; THALIDOMIDE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELB; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN;

APOPTOSIS; BINDING SITE; CANCER CELL CULTURE; CELL GROWTH; CELLULAR DISTRIBUTION; DNA BINDING; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; MUTATION; MYELOMA CELL; NOTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION;

CCAAT-ENHANCER-BINDING PROTEIN-BETA; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 21244470628     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.10.1326     Document Type: Note

References (21)

1. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and. requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83-5.
2. Hirata T, Shimazaki C, Sumikuma T, Ashihara E, Goto H, Inaba T, et al. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res 2003; 27:343-9.
3. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9:4653-65.
4. Lichtenstein A, Berenson J, Norman D, Chang M P, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74:1266-73.
5. Szczepek AJ, Belch AR, Pilarski LM. Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks. Exp Hematol 2001; 29:1076-81.
6. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97:483-9.
7. Xiao W, Hodge D, Wang L, Yang X, Zhang X, Farrar W. Co-operative functions between nuclear factors NFκB and CCAT/enhancer-binding protein-beta (C/EBP-β) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004; In press.
8. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel D S. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93:3044-52.
9. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-47.
10. Yamamoto Y, Gaynor R B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135-42.
11. Keifer J A, Guttridge D C, Ashburner B P, Baldwin A S, Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001; 276:22382-7.
12. Xiao W, Hodge D, Wang L, Yang X, Zhang X, Farrar W. NK-κB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFκB regulatory site in autocrine human multiple myeloma cells. Cancer Biol Ther 2004; In press.
13. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6:203-8.
14. Webb S J, McPherson J R, Pahan K, Koka S. Regulation of TNF-α-induced IL-6 production in MG-63 human osteoblast-like cells. J Dent Res 2002; 81:17-22.
15. Matt T. Transcriptional control of the inflammatory response: a role for the CREB-binding protein (CBP). Acta Med Austriaca 2002; 29:77-9.
16. Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R, et al. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood 1994; 84:3850-60.
17. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103:3148-57.
18. Karin M, Cao Y, Greten F R, Li Z W. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10.
19. Richardson P G, Barlogie B, Berenson J, Singhai S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
20. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-71.
21. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy M Q, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-23.